Retrophin (RTRX) PT Raised to $46 at BMO as Details Strengthen DUET Data

November 21, 2016 9:35 AM EST
Get Alerts RTRX Hot Sheet
Price: $19.97 +2.20%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade RTRX Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital analyst Do Kim reiterated an Outperform rating and raised his price target on Retrophin (NASDAQ: RTRX) to $46.00 (from $40.00) following positive updated DUET data at the ASN meeting.

Kim commented, "Our probability of success for Sparsentan increases to 55% from 45%, as we believe the results strengthen Retrophin's case for accelerated filing and launch in 2017. We believe the FDA will consider a dose titration for approval given an apparent dose-response in efficacy and tolerability (hypotension), with manageable edema rates. FDA acceptance of the proteinuria endpoint remains a risk, but we see growing evidence for proteinuria as a surrogate to kidney survival."

For an analyst ratings summary and ratings history on Retrophin click here. For more ratings news on Retrophin click here.

Shares of Retrophin closed at $20.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

BMO Capital

Add Your Comment